Rat pancreatic and intestinal sections with an antiserum for human GLP-1 (737) (Phoenix Pharmaceuticals, Mountain View, California, USA) at a concentration of 1/500
Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, producing potent metabolic effects observed in early clinical trials
This was done multiple times, excluding a different study in each instance
A 16-month randomized, placebo-controlled phase II clinical trial evaluated the safety and efficacy of 300, 600, or 1,200 mg/day of coenzyme Q 10 in 80 people with early Parkinson's disease (65)
DeCarli LM, Lieber CS: Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet
Ferrannini E, Mark M, Mayoux E